BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

CELZ upcoming catalysts

Creative Medical Technology Holdings Inc: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 0 readout(s) and 0 FDA event(s). Subscribe to CELZ (.ics).

Drugs: CELZ-201-DDT, CELZ-201 Administration

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01-20 est.P1/P2Creative Medical Technology Holdings Inc CELZNCT06053242 Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back PainChronic Low-back Pain; Degenerative Disc Diseaseactive not recruiting45
2027-01-31 est.P1/P2Creative Medical Technology Holdings Inc CELZNCT05626712 Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 DiabetesType 1 Diabetes; Diabetes Mellitus, Type 1recruiting18

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No readouts in the last 12 months.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.